Rob Veerhuis

List of Publications by Year
in descending order

113 papers	11,625 citations	43973 48 h-index	30848 102 g-index
134 all docs	134 docs citations	134 times ranked	14003 citing authors

#	Article	IF	Citations
1	Inflammation and Alzheimer's disease. Neurobiology of Aging, 2000, 21, 383-421.	1.5	4,069
2	The unfolded protein response is activated in Alzheimerâ€™s disease. Acta Neuropathologica, 2005, 110, 165-172.	3.9	488
3	Neuroinflammation in Alzheimer's disease and prion disease. Glia, 2002, 40, 232-239.	2.5	393
4	Complement in the brain. Molecular Immunology, 2011, 48, 1592-1603.	1.0	345
5	How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell, 2004, 3, 169-176.	3.0	319
6	Homogeneity of active demyelinating lesions in established multiple sclerosis. Annals of Neurology, 2008, 63, 16-25.	2.8	309
7	The significance of neuroinflammation in understanding Alzheimerâ€™s disease. Journal of Neural Transmission, 2006, 113, 1685-1695.	1.4	243
8	Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathologica, 2001, 101, 2-8.	3.9	229
9	Costimulatory Effects of Interferon-Î³ and Interleukin-1Î² or Tumor Necrosis Factor Î± on the Synthesis of AÎ²1-40 and AÎ²1-42 by Human Astrocytes. Neurobiology of Disease, 2000, 7, 682-689.	2.1	227
10	The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiology of Aging, 1996, 17, 673-680.	1.5	194
11	The Pathology of Multiple Sclerosis Is Location-Dependent: No Significant Complement Activation Is Detected in Purely Cortical Lesions. Journal of Neuropathology and Experimental Neurology, 2005, 64, 147-155.	0.9	165
12	Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer?s disease. Journal of Neural Transmission, 2003, 110, 949-955.	1.4	163
13	Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. International Journal of Developmental Neuroscience, 2006, 24, 157-165.	0.7	142
14	Cytokines Associated with Amyloid Plaques in Alzheimer's Disease Brain Stimulate Human Glial and Neuronal Cell Cultures to Secrete Early Complement Proteins, But Not C1-Inhibitor. Experimental Neurology, 1999, 160, 289-299.	2.0	140
15	Astrocytic AÎ²1â€42 uptake is determined by AÎ²â€aggregation state and the presence of amyloidâ€associated proteins. Glia, 2010, 58, 1235-1246.	2.5	139
16	Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiology of Aging, 2009, 30, 1885-1889.	1.5	135
17	Amyloid Î² plaque-associated proteins C1q and SAP enhance the AÎ²1â€“42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathologica, 2003, 105, 135-144.	3.9	129
18	Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology. Current Pharmaceutical Design, 2008, 14, 1419-1427.	0.9	128

#	Article	IF	Citations
19	Lipoprotein Receptor-Related Protein-1 Mediates Amyloid-Î²-Mediated Cell Death of Cerebrovascular Cells. American Journal of Pathology, 2007, 171, 1989-1999.	1.9	120
20	Cyclin D1 and Cyclin E Are Co-Localized with Cyclo-Oxygenase 2 (COX-2) in Pyramidal Neurons in Alzheimer Disease Temporal Cortex. Journal of Neuropathology and Experimental Neurology, 2002, 61, 678-688.	0.9	102
21	The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence. Current Alzheimer Research, 2011, 8, 142-150.	0.7	92
22	C1-inhibitor protects against brain ischemiaâ€“reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiology of Disease, 2005, 19, 10-17.	2.1	91
23	Whether, when and how chronic inflammation increases the risk of developing late-onset Alzheimer's disease. Alzheimer's Research and Therapy, 2012, 4, 15.	3.0	90
24	Binding and uptake of AÎ²1â€42 by primary human astrocytes in vitro. Glia, 2009, 57, 978-988.	2.5	86
25	The effect of amyloid associated proteins on the expression of genes involved in amyloid-Î² clearance by adult human astrocytes. Experimental Neurology, 2012, 233, 373-379.	2.0	81
26	NSAIDS inhibit the IL-1Î²-induced IL-6 release from human post-mortem astrocytes: the involvement of prostaglandin E2. Brain Research, 1997, 777, 210-218.	1.1	78
27	DNA Polymerase-beta Is Expressed Early in Neurons of Alzheimer's Disease Brain and Is Loaded into DNA Replication Forks in Neurons Challenged with beta-Amyloid. Journal of Neuroscience, 2006, 26, 10949-10957.	1.7	76
28	Inhibitory effect of minocycline on amyloid Î² fibril formation and human microglial activation. Glia, 2006, 53, 233-240.	2.5	75
29	BACE1 Activity in Cerebrospinal Fluid and Its Relation to Markers of AD Pathology. Journal of Alzheimer's Disease, 2010, 20, 253-260.	1.2	75
30	Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease. Current Drug Targets, 2003, 4, 461-468.	1.0	75
31	Isolation and characterization of adult microglial cells and oligodendrocytes derived from postmortem human brain tissue. Brain Research Protocols, 2000, 5, 85-94.	1.7	73
32	Interleukin-1Î² induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human neuroblastoma cells: implications for Alzheimer's disease. Experimental Gerontology, 2001, 36, 559-570.	1.2	72
33	Apolipoproteins E and J interfere with amyloidâ€beta uptake by primary human astrocytes and microglia in vitro. Glia, 2014, 62, 493-503.	2.5	71
34	Histological and Direct Evidence for the Role of Complement in the Neuroinflammation of AD. Current Alzheimer Research, 2011, 8, 34-58.	0.7	69
35	Early complement components in Alzheimer's disease brains. Acta Neuropathologica, 1995, 91, 53-60.	3.9	68
36	Distribution of beta amyloid associated proteins in plaques in Alzheimer's disease and in the non-demented elderly. Experimental Neurology, 1995, 4, 291-297.	1.7	62

#	Article	IF	Citations
37	Distribution of AÎ²-associated proteins in cerebrovascular amyloid of Alzheimer's disease. Acta Neuropathologica, 1998, 96, 628-636.	3.9	61
38	Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1995, 426, 603-610.	1.4	60
39	Complement C1-inhibitor expression in Alzheimer's disease. Acta Neuropathologica, 1998, 96, 287-296.	3.9	60
40	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimerâ€™s Disease in Non-Demented Elderly. Journal of Alzheimer's Disease, 2017, 56, 687-697.	1.2	60
41	<scp>Î±â€Synuclein</scp> evokes <scp>NLRP3</scp> inflammasomeâ€mediated <scp>IL</scp>â€1Î² secretion from primary human microglia. Glia, 2021, 69, 1413-1428.	2.5	58
42	Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiology of Disease, 2004, 15, 492-499.	2.1	57
43	Amyloid Associated Proteins in Alzheimers and Prion Disease. CNS and Neurological Disorders, 2005, 4, 235-248.	4.3	55
44	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 1011.e1-1011.e9.	1.5	55
45	Clusterin Levels in Plasma Predict Cognitive Decline and Progression to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 1103-1110.	1.2	55
46	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. Neurobiology of Aging, 2012, 33, 1591-1598.	1.5	52
47	Amyloid-Î² Oligomers Relate to Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 35-43.	1.2	52
48	The unfolded protein response affects neuronal cell cycle protein expression: Implications for Alzheimer's disease pathogenesis. Experimental Gerontology, 2006, 41, 380-386.	1.2	51
49	Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. European Journal of Neurology, 2011, 18, 865-871.	1.7	51
50	Minocycline does not affect amyloid Î² phagocytosis by human microglial cells. Neuroscience Letters, 2007, 416, 87-91.	1.0	50
51	NG2 cells, a new trail for Alzheimerâ€™s disease mechanisms?. Acta Neuropathologica Communications, 2013, 1, 7.	2.4	50
52	Amyloid Î² peptide (25â€“35) activates protein kinase C leading to cyclooxygenase-2 induction and prostaglandin E2 release in primary midbrain astrocytes. Neurochemistry International, 2006, 48, 663-672.	1.9	48
53	Neuroinflammation in Plaque and Vascular Î²-Amyloid Disorders: Clinical and Therapeutic Implications. Neurodegenerative Diseases, 2008, 5, 190-193.	0.8	48
54	Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue. Journal of Neuroimmunology, 2015, 278, 271-276.	1.1	48

#	Article	IF	Citations
55	C4b-binding protein in Alzheimer's disease: Binding to AÎ²1â€“42 and to dead cells. Molecular Immunology, 2008, 45, 3649-3660.	1.0	46
56	ATP-binding cassette transporters P-glycoprotein and breast cancer related protein are reduced in capillary cerebral amyloid angiopathy. Neurobiology of Aging, 2014, 35, 565-575.	1.5	46
57	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1596-1604.	1.5	46
58	Apolipoprotein E protects cultured pericytes and astrocytes from D-AÎ²1â€“40-mediated cell death. Brain Research, 2010, 1315, 169-180.	1.1	45
59	Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. Journal of Neuroinflammation, 2005, 2, 27.	3.1	44
60	Biomarkers of inflammation and amyloid-Î² phagocytosis in patients at risk of Alzheimer disease. Experimental Gerontology, 2010, 45, 57-63.	1.2	44
61	The Pre-Eclampsia Gene STOX1 Controls a Conserved Pathway in Placenta and Brain Upregulated in Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 673-679.	1.2	40
62	Small heat shock proteins associated with cerebral amyloid angiopathy of hereditary cerebral hemorrhage with amyloidosis (Dutch type) induce interleukin-6 secretion. Neurobiology of Aging, 2009, 30, 229-240.	1.5	39
63	Additional Value of CSF Amyloid-Î²40 Levels in the Differentiation between FTLD and Control Subjects. Journal of Alzheimer's Disease, 2010, 20, 445-452.	1.2	39
64	Establishment of microglial cell cultures derived from postmortem human adult brain tissue: Immunophenotypical and functional characterization. Microscopy Research and Technique, 2001, 54, 34-39.	1.2	38
65	Microglia kill amyloid-Î²1-42 damaged neurons by a CD14-dependent process. NeuroReport, 2004, 15, 1427-1430.	0.6	37
66	Increased Aβ1-42 Production Sensitizes Neuroblastoma Cells for ER Stress Toxicity. Current Alzheimer Research, 2008, 5, 469-474.	0.7	36
67	Small Heat Shock Proteins Induce a Cerebral Inflammatory Reaction. Journal of Neuroscience, 2011, 31, 11992-12000.	1.7	36
68	Soothing the Inflamed Brain: Effect of Non-Steroidal Anti-Inflammatory Drugs on Alzheimers Disease Pathology. CNS and Neurological Disorders - Drug Targets, 2011, 10, 57-67.	0.8	34
69	CSF markers related to pathogenetic mechanisms in Alzheimer's disease. Journal of Neural Transmission, 2002, 109, 1491-1498.	1.4	32
70	Interleukin-1 beta-induced expression of the prostaglandin E2-receptor subtype EP3 in U373 astrocytoma cells depends on protein kinase C and nuclear factor-kappaB. Journal of Neurochemistry, 2006, 96, 680-693.	2.1	31
71	Goodpasture Antigen-binding Protein/Ceramide Transporter Binds to Human Serum Amyloid P-Component and Is Present in Brain Amyloid Plaques. Journal of Biological Chemistry, 2012, 287, 14897-14911.	1.6	31
72	Adult human microglia secrete cytokines when exposed to neurotoxic prion protein peptide: no intermediary role for prostaglandin E2. Brain Research, 2002, 925, 195-203.	1.1	30

#	Article	IF	Citations
73	Decreased cerebrospinal fluid amyloid beta (1-40) levels in frontotemporal lobar degeneration. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 78, 735-737.	0.9	30
74	APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 65.	3.0	28
75	C-reactive protein and complement depositions in human infarcted myocardium are more extensive in patients with reinfarction or upon treatment with reperfusion. European Journal of Clinical Investigation, 2004, 34, 803-810.	1.7	27
76	Serum Amyloid P Component as a Biomarker in Mild Cognitive Impairment and Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2008, 26, 522-527.	0.7	27
77	Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1079-1083.	1.1	26
78	CSF ApoE predicts clinical progression in nondemented APOEÎµ4 carriers. Neurobiology of Aging, 2017, 57, 186-194.	1.5	26
79	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinsonâ€™s disease. Journal of Neuroinflammation, 2022, 19, 50.	3.1	26
80	Discriminatory and predictive capabilities of enzymeâ€linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. Alzheimer's and Dementia, 2013, 9, 276-283.	0.4	25
81	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. Frontiers in Neurology, 2015, 6, 202.	1.1	24
82	Activation of human microglia by fibrillar prion protein-related peptides is enhanced by amyloid-associated factors SAP and C1q. Neurobiology of Disease, 2005, 19, 273-282.	2.1	21
83	Quantification of amyloid-beta 40 in cerebrospinal fluid. Journal of Immunological Methods, 2009, 348, 57-66.	0.6	21
84	Evaluation of Intrathecal Serum Amyloid P (SAP) and C-Reactive Protein (CRP) Synthesis in Alzheimer's Disease with the Use of Index Values. Journal of Alzheimer's Disease, 2011, 22, 1073-1079.	1.2	21
85	Complement Activation by Ceramide Transporter Proteins. Journal of Immunology, 2014, 192, 1154-1161.	0.4	21
86	AÎ²-oligomer uptake and the resulting inflammatory response in adult human astrocytes are precluded by an anti-AÎ² single chain variable fragment in combination with an apoE mimetic peptide. Molecular and Cellular Neurosciences, 2018, 89, 49-59.	1.0	21
87	Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT studyâœ°. Journal of Affective Disorders, 2019, 256, 509-516.	2.0	20
88	Inflammation in older subjects with early- and late-onset depression in the NESDO study: a cross-sectional and longitudinal case-only design. Psychoneuroendocrinology, 2019, 99, 20-27.	1.3	19
89	The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, 32.	2.5	19
90	Immunological Aspects of Alzheimer??s Disease. BioDrugs, 2001, 15, 325-337.	2.2	18

#	Article	IF	Citations
91	Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid Î²-peptide. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2013, 20, 179-187.	1.4	18
92	Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of AÎ² by insulin degrading enzyme (IDE) in Alzheimerâ€™s disease. Neuroscience Letters, 2015, 589, 47-51.	1.0	13
93	Impaired Innate Immunity Mechanisms in the Brain of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2020, 21, 1126.	1.8	13
94	Quantification of clusterin in paired cerebrospinal fluid and plasma samples. Annals of Clinical Biochemistry, 2014, 51, 557-567.	0.8	12
95	Effects of an AÎ²-antibody fragment on AÎ² aggregation and astrocytic uptake are modulated by apolipoprotein E and J mimetic peptides. PLoS ONE, 2017, 12, e0188191.	1.1	12
96	ApoE and clusterin CSF levels influence associations between APOEÂgenotype and changes in CSF tau, but not CSF AÎ²42, levels inÂnon-demented elderly. Neurobiology of Aging, 2019, 79, 101-109.	1.5	12
97	Inflammation and Cognitive Functioning in Depressed Older Adults Treated With Electroconvulsive Therapy. Journal of Clinical Psychiatry, 2021, 82, .	1.1	11
98	ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. Journal of the American Geriatrics Society, 2007, 55, 956-958.	1.3	10
99	CSF levels of PSA and PSAâ€“ACT complexes in Alzheimer's disease. Annals of Clinical Biochemistry, 2009, 46, 477-483.	0.8	9
100	S100 calcium-binding protein B in older patients with depression treated with electroconvulsive therapy. Psychoneuroendocrinology, 2019, 110, 104414.	1.3	5
101	The pattern of inflammatory markers during electroconvulsive therapy in older depressed patients. World Journal of Biological Psychiatry, 2021, 22, 770-777.	1.3	4
102	Aminobisphosphonates inhibit dendritic cell-mediated antigen-specific activation of CD1d-restricted iNKT cells. Clinical Immunology, 2015, 158, 92-99.	1.4	2
103	Role of Inflammation and Complement Activation in Alzheimer's Disease. , 1995, , 171-193.		2
104	P3-031: AMYLOID-BETA DEGRADATION BY HUMAN ASTROCYTES IS IMPAIRED BY APOJ AND APOE. , 2014, 10, P638-P638.		1
105	The Involvement of AÎ² in the Neuroinflammatory Response. , 2007, , 52-82.		1
106	Neuroinflammation in Early Stages of Alzheimerâ€™s Disease and Parkinsonâ€™s Disease. , 2008, , 113-121.		0
107	Preferential uptake of amyloid beta 1â€“42 oligomers by primary human astrocytes in vitro: Influence of SAP and C1q. Molecular Immunology, 2009, 46, 2860.	1.0	0
108	Inflammatory markers in AD and MCI patients with different biomarker profilesâ€”interpretation of serum and CSF levels. Neurobiology of Aging, 2010, 31, 1655.	1.5	0

#	Article	IF	Citations
109	2.131 CSF CLUSTERIN IS ASSOCIATED WITH COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE BIOMARKERS IN PARKINSON'S DISEASE PATIENTS. Parkinsonism and Related Disorders, 2012, 18, S109.	1.1	0
110	O2-13-05: APOLIPOPROTEIN A-1 IS ASSOCIATED WITH DECLINE IN PRECLINICAL AD. , 2014, 10, P195-P196.		0
111	P1-096: IRAK-4 KINASE INHIBITION REDUCES PRO-INFLAMMATORY CYTOKINE SECRETION BUT HAS NO EFFECT ON THE UPTAKE OF AMYLOID BETA BY HUMAN GLIAL CELLS. , 2014, 10, P337-P337.		0
112	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins?. , 2015, 11, P644-P644.		0
113	[P3â€“161]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL AÎ² CLEARANCE?. Alzheimer's and Dementia, 2017, 13, P995.	0.4	0